Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Dynatronics Corporation manufactures and distributes physical therapy and rehabilitation equipment, including electrotherapy devices, treatment tables, therapeutic modalities, and orthopedic soft goods. The company serves physical therapists, chiropractors, athletic trainers, and orthopedic specialists primarily in the U.S. market. With a market cap under $10M, deteriorating margins (21.9% gross, -39.8% net), and 67.7% stock decline over 12 months, the company faces severe financial distress with negative ROE of -136.9% and high leverage (2.26 D/E ratio).
Dynatronics operates a low-margin distribution model selling capital equipment and consumables to healthcare practitioners. Revenue is generated through direct sales force targeting clinics, hospitals, and sports medicine facilities, plus dealer/distributor networks. The company faces intense pricing pressure from larger competitors (DJO Global, Patterson Medical) and lacks differentiated technology. With 21.9% gross margins (well below medical device industry average of 60-70%), the business model suggests commodity-like products with limited pricing power. The -15.8% revenue decline and -39.8% net margin indicate structural profitability challenges and potential market share loss.
Quarterly revenue trends and ability to stabilize declining sales (-15.8% YoY)
Gross margin trajectory - any improvement from 21.9% would signal pricing power or cost control
Debt refinancing announcements or covenant compliance given 2.26 D/E ratio and negative cash generation
Healthcare capital equipment spending trends, particularly in outpatient physical therapy and sports medicine facilities
Acquisition rumors or strategic alternatives given distressed valuation (0.2x P/B, -0.7x EV/EBITDA)
Commoditization of physical therapy equipment with limited product differentiation versus larger competitors (DJO Global, Zimmer Biomet rehabilitation division)
Shift toward value-based care and bundled payments reducing healthcare facility capital budgets for non-essential equipment
Consolidation in physical therapy clinic market creating larger buyers with enhanced negotiating power
Potential for at-home rehabilitation technology and telehealth reducing demand for clinic-based equipment
Scale disadvantage versus multi-billion dollar medical device conglomerates with broader product portfolios and R&D budgets
Inability to invest in product innovation given negative cash flow and distressed balance sheet
Market share loss evidenced by -15.8% revenue decline while broader medical device market grows mid-single digits
Pricing pressure from online distributors and direct-to-consumer rehabilitation products
Severe financial distress: -136.9% ROE, -78.5% ROA, negative operating and free cash flow
High leverage (2.26 D/E) with limited refinancing options given operating losses
Liquidity concerns with 1.07 current ratio barely covering short-term obligations
Going concern risk - market cap under $10M with negative $0.0B cash flow suggests potential bankruptcy or forced sale
Equity dilution risk if company raises capital to avoid default
moderate-to-high - Physical therapy equipment purchases are discretionary capital expenditures for clinics and hospitals. During economic downturns, healthcare facilities defer equipment upgrades, impacting sales. However, the business benefits from aging demographics (Medicare-eligible population) and sports medicine growth trends. The company's current distress amplifies cyclical sensitivity as weak demand compounds existing operational challenges.
High sensitivity through multiple channels: (1) Elevated debt levels (2.26 D/E) make refinancing costs critical to survival - rising rates increase interest expense on what appears to be distressed debt; (2) Customer financing availability affects capital equipment purchases by small clinics; (3) Valuation multiples compress as risk-free rates rise, particularly problematic given negative earnings. Current rate environment (February 2026) with restrictive Fed policy likely pressures both operations and stock valuation.
Critical - The company's negative cash flow, high leverage, and deteriorating fundamentals suggest significant refinancing risk. Access to credit markets and covenant compliance are existential issues. Customer credit quality matters less than the company's own ability to secure working capital financing and refinance existing debt obligations.
Distressed/special situations investors and deep value speculators betting on turnaround or liquidation value. The 0.2x P/B ratio, -67.7% one-year return, and 66.9% FCF yield (likely distorted by negative denominators) attract bankruptcy arbitrage funds and restructuring specialists rather than traditional growth or income investors. Extreme volatility and binary outcomes (restructuring success versus bankruptcy) characterize the opportunity set.
high - Micro-cap stock with severe financial distress exhibits extreme volatility. The -59.3% six-month and -67.7% one-year returns demonstrate downside volatility, while any positive news (debt restructuring, strategic buyer interest) could generate triple-digit percentage moves on low liquidity. Daily trading volumes likely minimal, amplifying price swings.